Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone.

AUTOR(ES)

Cormican, M G

RESUMO

Compound LB20304 is a fluoronaphthyridone carboxylic acid with a novel pyrrolidine substituent. This drug was compared with ciprofloxacin, levofloxacin, ofloxacin, and trovafloxacin against over 800 pathogens, most from blood stream infections, by National Committee for Clinical Laboratory Standards reference methods. LB20304 was the most active agent against gram-positive species including strains observed to be resistant to other fluoroquinolones and glycopeptides. The potency of LB20304 (MIC50, 0.03 micrograms/ml) against the Enterobacteriaceae was exceeded only by that of ciprofloxacin (0.015 micrograms/ml). It has limited activity against gram-negative anaerobes.

Documentos Relacionados

• In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.
• In vitro and in vivo antibacterial activities of BMY 40062, a new fluoronaphthyridone.
• Identification and Characteristics of a Novel Burkholderia Strain with Broad-Spectrum Antimicrobial Activity
• Activities of Gemifloxacin (SB 265805, LB20304) Compared to Those of Other Oral Antimicrobial Agents against Unusual Anaerobes
• In Vitro Activity of Gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and Its Pharmacokinetics in Guinea Pigs with L. pneumophila Pneumonia